277 related articles for article (PubMed ID: 33553571)
1. The screening and evaluation of potential clinically significant HIV drug combinations against the SARS-CoV-2 virus.
Tomić D; Davidović D; Szasz AM; Rezeli M; Pirkić B; Petrik J; Vrca VB; Janđel V; Lipić T; Skala K; Mesarić J; Periša MM; Šojat Z; Rogina BM
Inform Med Unlocked; 2021; 23():100529. PubMed ID: 33553571
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
[TBL] [Abstract][Full Text] [Related]
3. Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors.
Romeo A; Iacovelli F; Falconi M
Virus Res; 2020 Sep; 286():198068. PubMed ID: 32565126
[TBL] [Abstract][Full Text] [Related]
4.
Gurung AB
Gene Rep; 2020 Dec; 21():100860. PubMed ID: 32875166
[TBL] [Abstract][Full Text] [Related]
5. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
[TBL] [Abstract][Full Text] [Related]
6. In silico identification of strong binders of the SARS-CoV-2 receptor-binding domain.
Behloul N; Baha S; Guo Y; Yang Z; Shi R; Meng J
Eur J Pharmacol; 2021 Jan; 890():173701. PubMed ID: 33130279
[TBL] [Abstract][Full Text] [Related]
7. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
8. Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy.
Shamsi A; Mohammad T; Anwar S; AlAjmi MF; Hussain A; Rehman MT; Islam A; Hassan MI
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32441299
[TBL] [Abstract][Full Text] [Related]
9. Repurposing of FDA-Approved Toremifene to Treat COVID-19 by Blocking the Spike Glycoprotein and NSP14 of SARS-CoV-2.
Martin WR; Cheng F
J Proteome Res; 2020 Nov; 19(11):4670-4677. PubMed ID: 32907334
[TBL] [Abstract][Full Text] [Related]
10. In Silico Drug Repurposing for SARS-CoV-2 Main Proteinase and Spike Proteins.
Maffucci I; Contini A
J Proteome Res; 2020 Nov; 19(11):4637-4648. PubMed ID: 32893632
[TBL] [Abstract][Full Text] [Related]
11. Lack of antiviral activity of darunavir against SARS-CoV-2.
De Meyer S; Bojkova D; Cinatl J; Van Damme E; Buyck C; Van Loock M; Woodfall B; Ciesek S
Int J Infect Dis; 2020 Aug; 97():7-10. PubMed ID: 32479865
[TBL] [Abstract][Full Text] [Related]
12. [Umifenovir and coronavirus infections: a review of research results and clinical practice].
Leneva IA; Pshenichnaya NY; Bulgakova VA
Ter Arkh; 2020 Dec; 92(11):91-97. PubMed ID: 33720612
[TBL] [Abstract][Full Text] [Related]
13. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.
Choudhury A; Mukherjee S
J Med Virol; 2020 Oct; 92(10):2105-2113. PubMed ID: 32383269
[TBL] [Abstract][Full Text] [Related]
14. [Homologous modeling and binding ability analysis of Spike protein after point mutation of severe acute respiratory syndrome coronavirus 2 to receptor proteins and potential antiviral drugs].
Cao Z; Wang LT; Liu ZM
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 53(1):150-158. PubMed ID: 33550350
[TBL] [Abstract][Full Text] [Related]
15. Structure-based drug designing for potential antiviral activity of selected natural products from Ayurveda against SARS-CoV-2 spike glycoprotein and its cellular receptor.
Maurya VK; Kumar S; Prasad AK; Bhatt MLB; Saxena SK
Virusdisease; 2020 Jun; 31(2):179-193. PubMed ID: 32656311
[TBL] [Abstract][Full Text] [Related]
16. Structure-Based Virtual Screening and Biochemical Validation to Discover a Potential Inhibitor of the SARS-CoV-2 Main Protease.
Gupta A; Rani C; Pant P; Vijayan V; Vikram N; Kaur P; Singh TP; Sharma S; Sharma P
ACS Omega; 2020 Dec; 5(51):33151-33161. PubMed ID: 33398250
[TBL] [Abstract][Full Text] [Related]
17. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
18. Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications.
Farsalinos K; Eliopoulos E; Leonidas DD; Papadopoulos GE; Tzartos S; Poulas K
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823591
[TBL] [Abstract][Full Text] [Related]
19. Neutralization of SARS-CoV-2 Spike Protein via Natural Compounds: A Multilayered High Throughput Virtual Screening Approach.
Dhasmana A; Kashyap VK; Dhasmana S; Kotnala S; Haque S; Ashraf GM; Jaggi M; Yallapu MM; Chauhan SC
Curr Pharm Des; 2020; 26(41):5300-5309. PubMed ID: 32867645
[TBL] [Abstract][Full Text] [Related]
20. Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods.
Unni S; Aouti S; Thiyagarajan S; Padmanabhan B
J Biosci; 2020; 45(1):. PubMed ID: 33184246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
